Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 87,551,208
  • Shares Outstanding, K 1,632,200
  • Annual Sales, $ 20,776 M
  • Annual Income, $ 1,007 M
  • 36-Month Beta 1.11
  • Price/Sales 4.21
  • Price/Cash Flow 15.19
  • Price/Book 6.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.84
  • Number of Estimates 6
  • High Estimate 0.85
  • Low Estimate 0.81
  • Prior Year 0.68
  • Growth Rate Est. (year over year) +23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.86 +4.53%
on 11/27/18
54.81 -4.91%
on 11/16/18
-0.47 (-0.89%)
since 11/14/18
3-Month
46.94 +11.04%
on 10/25/18
63.69 -18.17%
on 10/09/18
-8.57 (-14.12%)
since 09/14/18
52-Week
46.94 +11.04%
on 10/25/18
70.05 -25.60%
on 02/16/18
-10.01 (-16.11%)
since 12/14/17

Most Recent Stories

More News
Marizyme, Inc., Appoints New Members to its Board of Directors

Marizyme, Inc. ("Marizyme" or the "Company"), a publicly traded (OTC:MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space for development and commercialization, announced...

TBRA : 42.09 (+0.65%)
MRZM : 1.2500 (-3.10%)
BMY : 52.12 (-2.83%)
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus

AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.

AZN : 39.15 (-0.23%)
JNJ : 133.00 (-10.04%)
LLY : 111.93 (-2.55%)
NVS : 87.39 (-1.14%)
RHHBY : 31.0900 (-2.54%)
PFE : 43.80 (-1.73%)
BMY : 52.12 (-2.83%)
Today's Research Reports on Trending Tickers: Bristol-Myers Squibb and Novartis

NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial...

BMY : 52.12 (-2.83%)
Zacks.com featured highlights include: Nexstar Media, Bristol-Myers Squibb, Capital One Financial, Helmerich & Payne and Progressive

Zacks.com featured highlights include: Nexstar Media, Bristol-Myers Squibb, Capital One Financial, Helmerich & Payne and Progressive

HP : 58.48 (-3.82%)
PGR : 62.00 (-1.82%)
COF : 78.73 (-2.06%)
BMY : 52.12 (-2.83%)
NXST : 85.00 (-0.84%)
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know

Bristol-Myers Squibb (BMY) closed at $53.64 in the latest trading session, marking a +0.37% move from the prior day.

BMY : 52.12 (-2.83%)
HIV Attachment Inhibitor Pipeline Insights Report 2018 Featuring Bristol-Myers Squibb, HSRx Biopharmaceutical, Osel Inc & AnGes MG - ResearchAndMarkets.com

The "HIV Attachment Inhibitor - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

AMGXF : 5.5500 (-10.48%)
BMY : 52.12 (-2.83%)
Anti-CD28 Antibody Pipeline Insight Report 2018 Featuring Alpine Immune Sciences, Janssen Biotech, Bayer HealthCare Pharmaceuticals & Bristol-Myers Squibb - ResearchAndMarkets.com

The "Anti-CD28 Antibody - Pipeline Insight, 2018" drug pipeline has been added to ResearchAndMarkets.com's offering.

ALPN : 4.80 (-0.31%)
BMY : 52.12 (-2.83%)
J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study

J&J's (JNJ) psoriasis drug Tremfya proves to be better than Novartis' Cosentyx in phase III head-to-head study for treating adult patients with moderate to severe plaque psoriasis.

MRK : 76.48 (-3.20%)
JNJ : 133.00 (-10.04%)
NVS : 87.39 (-1.14%)
BMY : 52.12 (-2.83%)
Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA

Mallinckrodt (MNK) receives complete response letter from the FDA related to its regulatory application seeking approval for abuse-deterrent reformulation of opioid painkiller, Roxicodone.

JNJ : 133.00 (-10.04%)
MRK : 76.48 (-3.20%)
MNK : 19.20 (-7.78%)
BMY : 52.12 (-2.83%)
Upgraded Broker Ratings Make These 5 Stocks Worth a Look Now

Following what the majority of brokers are saying about a particular stock can help understand its potential. Hence, when a broker upgrades a stock, one can easily rely on it.

HP : 58.48 (-3.82%)
PGR : 62.00 (-1.82%)
COF : 78.73 (-2.06%)
BMY : 52.12 (-2.83%)
NXST : 85.00 (-0.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 53.77
1st Resistance Point 52.94
Last Price 52.12
1st Support Level 51.61
2nd Support Level 51.11

See More

52-Week High 70.05
Fibonacci 61.8% 61.22
Fibonacci 50% 58.50
Fibonacci 38.2% 55.77
Last Price 52.12
52-Week Low 46.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar